FUS (fused in sarcoma) is a DNA/RNA binding protein, which contains a nuclear localization sequence in its C-terminal. A QGSY (glutamine-glycine-serine-tyrosine)-rich region is localized to its N-terminal, which plays an essential role in the self-assembly of this protein. It was first identified in liposarcomas as a fusion protein.
Synonyms: Anti-ALS6; Anti-FUS1; Anti-HNRNPP2; Anti-TLS; Anti-hnRNP-P2
Storage: -20C
Application: Anti-FUS antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Mutations in FUS (fused in sarcoma) gene result in a subset of familial amyotrophic lateral sclerosis (ALS). This disease is characterized by the accumulation of FUS aggregates in the cytosol due to mutations clustered in its nuclear localization sequence. This protein is multifunctional and plays multiple roles in the metabolism of RNA. In liposarcomas, the N-terminal of this protein fuses with the N-terminal of the CHOP (CCAAT-enhancer-binding protein homologous protein) transcription factor, which results in tumorigenesis through the activation of oncogenes. This protein is associated with the pathogenesis of neurodegeneration, and its inactivation influences the homeostasis of cells. Inactivation of this protein leads to an elevation in the phosphorylation og histone H3, which leads to cell arrest, thus, impacting cell proliferation.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC